Business Wire

Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease at AAIC 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage neurotechnology company pioneering neuromodulation-based treatments for neurodegenerative diseases, announced five new poster ...
Morningstar

Cognito Therapeutics Announces Presentation of New CSF Proteomic and EEG Biomarker Data for Spectris™ in Alzheimer’s Disease at CTAD 2025

Cognito Therapeutics Announces Presentation of New CSF Proteomic and EEG Biomarker Data for Spectris™ in Alzheimer’s Disease at CTAD 2025 Cognito Therapeutics, a clinical-stage medical device company ...
Business Wire

Cognito Therapeutics Presents Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety, Adherence and Durability of Treatment Benefits Over 18 Months

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a late-stage developer of disease-modifying therapies to treat neurodegenerative disorders, announced today continued active treatment in the ...